JP2019534710A5 - - Google Patents

Download PDF

Info

Publication number
JP2019534710A5
JP2019534710A5 JP2019538102A JP2019538102A JP2019534710A5 JP 2019534710 A5 JP2019534710 A5 JP 2019534710A5 JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019538102 A JP2019538102 A JP 2019538102A JP 2019534710 A5 JP2019534710 A5 JP 2019534710A5
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
set forth
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019538102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019534710A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/053880 external-priority patent/WO2018064255A2/en
Publication of JP2019534710A publication Critical patent/JP2019534710A/ja
Publication of JP2019534710A5 publication Critical patent/JP2019534710A5/ja
Priority to JP2022105725A priority Critical patent/JP2022141693A/ja
Pending legal-status Critical Current

Links

Images

JP2019538102A 2016-09-28 2017-09-28 インターロイキン2に結合する抗体およびその使用 Pending JP2019534710A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022105725A JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662401158P 2016-09-28 2016-09-28
US62/401,158 2016-09-28
US201662421038P 2016-11-11 2016-11-11
US62/421,038 2016-11-11
PCT/US2017/053880 WO2018064255A2 (en) 2016-09-28 2017-09-28 Antibodies that bind interleukin-2 and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022105725A Division JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Publications (2)

Publication Number Publication Date
JP2019534710A JP2019534710A (ja) 2019-12-05
JP2019534710A5 true JP2019534710A5 (enExample) 2020-11-12

Family

ID=60117762

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019538102A Pending JP2019534710A (ja) 2016-09-28 2017-09-28 インターロイキン2に結合する抗体およびその使用
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022105725A Pending JP2022141693A (ja) 2016-09-28 2022-06-30 インターロイキン2に結合する抗体およびその使用

Country Status (13)

Country Link
US (2) US10858428B2 (enExample)
EP (1) EP3518969A2 (enExample)
JP (2) JP2019534710A (enExample)
KR (1) KR20190057113A (enExample)
CN (1) CN110087681A (enExample)
AU (1) AU2017335771A1 (enExample)
BR (1) BR112019005944A2 (enExample)
CA (1) CA3038679A1 (enExample)
IL (1) IL265323A (enExample)
MX (1) MX2019003543A (enExample)
PH (1) PH12019500643A1 (enExample)
WO (1) WO2018064255A2 (enExample)
ZA (1) ZA201901892B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017335771A1 (en) * 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
US20220296705A1 (en) * 2019-08-09 2022-09-22 Riken Combined use of artificial adjuvant vector cells and an immunostimulant
CN115397852B (zh) * 2020-02-16 2023-08-11 奥罗斯生物科学公司 工程化抗il-2抗体
CN111499746B (zh) * 2020-04-28 2020-11-24 优睿赛思(武汉)生物科技有限公司 一种针对人白介素-2的高亲和力兔单克隆抗体及其应用
CN114441763A (zh) * 2020-10-30 2022-05-06 江苏恒瑞医药股份有限公司 一种白细胞介素2的检测方法
US20230414720A1 (en) * 2020-11-23 2023-12-28 University Of Florida Research Foundation, Incorporated Use of insulin-like growth factors with gamma-chain cytokines to induce homeostatic proliferation of lymphocytes
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
CN115850471A (zh) * 2022-10-13 2023-03-28 深圳市百士通科技开发有限公司 一种抗人il-2单克隆抗体及其应用
CN118440194B (zh) * 2024-05-23 2024-11-26 武汉爱博泰克生物科技有限公司 用于检测鼠白介素-2的抗体、抗体对及检测试剂或试剂盒

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
EP0272253A4 (en) 1986-03-07 1990-02-05 Massachusetts Inst Technology METHOD FOR IMPROVING GLYCOPROTE INSTABILITY.
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DK0494955T3 (da) 1989-10-05 1998-10-26 Optein Inc Cellefri syntese og isolering af hidtil ukendte gener og polypeptider
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
ES2087997T3 (es) 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JPH06508511A (ja) 1990-07-10 1994-09-29 ケンブリッジ アンティボディー テクノロジー リミティド 特異的な結合ペアーの構成員の製造方法
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233769D1 (de) 1991-03-01 2009-09-24 Dyax Corp Chimäres Protein mit Mikroprotein mit zwei oder mehr Disulfidbindungen und Ausgestaltungen davon
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5348867A (en) 1991-11-15 1994-09-20 George Georgiou Expression of proteins on bacterial surface
JPH07501451A (ja) 1991-11-25 1995-02-16 エンゾン・インコーポレイテッド 多価抗原結合タンパク質
EP1291360A1 (en) 1991-12-13 2003-03-12 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
JP3571337B2 (ja) 1992-02-11 2004-09-29 セル ジェネシス,インコーポレーテッド 遺伝子標的現象による同型遺伝子接合
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
JPH07509137A (ja) 1992-07-24 1995-10-12 セル ジェネシス,インク. 異種抗体の生産
US6664114B1 (en) 1992-08-03 2003-12-16 Sapidyne Instruments, Inc. Solid phase assay for detection of ligands
AU689755B2 (en) 1992-09-22 1998-04-09 Biofocus Discovery Limited Recombinant viruses displaying a nonviral polypeptide on their external surface
US6054287A (en) 1994-05-27 2000-04-25 Methodist Hospital Of Indiana, Inc. Cell-type-specific methods and devices for the low temperature preservation of the cells of an animal species
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
GB9712818D0 (en) 1996-07-08 1997-08-20 Cambridge Antibody Tech Labelling and selection of specific binding molecules
EP2305027B1 (en) 1996-12-03 2014-07-02 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス,インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
EP1433793A4 (en) 2001-09-13 2006-01-25 Inst Antibodies Co Ltd METHOD FOR CREATING A CAMEL ANTIBODY LIBRARY
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CN1326879C (zh) 2002-03-29 2007-07-18 先灵公司 人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
NZ563213A (en) 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
DE602006004047D1 (de) 2005-06-03 2009-01-15 Metso Paper Inc Verfahren und vorrichtung zur mechanischen entfaserung von holz
US20100310501A1 (en) 2006-02-16 2010-12-09 Onur Boyman Methods for Improving Immune Function and Methods for Prevention or Treatment of Disease in a Mammalian Subject
CA2656700A1 (en) 2006-07-06 2008-01-10 Merck Patent Gesellschaft Mit Beschraenkter Haftung Compositions and methods for enhancing the efficacy of il-2 mediated immune responses
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
CU23734A1 (es) 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
HRP20210642T1 (hr) 2010-11-12 2021-05-28 Nektar Therapeutics Konjugati il-2 ostatka i polimera
US9266938B2 (en) 2011-02-10 2016-02-23 Roche Glycart Ag Mutant interleukin-2 polypeptides
EP3954704A1 (en) 2011-06-03 2022-02-16 XOMA Technology Ltd. Antibodies specific for tgf-beta
WO2013177187A2 (en) 2012-05-22 2013-11-28 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
WO2014100014A1 (en) 2012-12-17 2014-06-26 The Board Of Trustees Of The Leland Stanford Junior University Super-2 complexes with antibody to augment il-2 therapy
US10826982B2 (en) 2013-01-10 2020-11-03 Nxp Usa, Inc. Packet processing architecture and method therefor
WO2015109212A1 (en) * 2014-01-17 2015-07-23 Pfizer Inc. Anti-il-2 antibodies and compositions and uses thereof
CN111423513A (zh) 2014-02-06 2020-07-17 豪夫迈·罗氏有限公司 白介素-2融合蛋白和其用途
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
AU2015287227B2 (en) * 2014-07-10 2021-02-18 Universitat Zurich Immune-stimulating monoclonal antibodies against human interleukin-2
MA40094B1 (fr) 2014-08-06 2022-05-31 Univ Miami Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation
WO2016030350A1 (en) 2014-08-29 2016-03-03 F. Hoffmann-La Roche Ag Combination therapy of tumor-targeted il-2 variant immunocytokines and antibodies against human pd-l1
KR102876923B1 (ko) * 2015-10-23 2025-10-28 화이자 인코포레이티드 항-il-2 항체 및 조성물 및 이의 용도
BR112018014150A2 (en) * 2016-01-11 2018-12-11 Novartis Ag immunostimulating humanized monoclonal antibodies to human interleukin-2, and fusion proteins thereof
AU2017335771A1 (en) * 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof

Similar Documents

Publication Publication Date Title
JP2019534710A5 (enExample)
Strohl Current progress in innovative engineered antibodies
US10561653B2 (en) 5-bromo-2,6-di-(1H-pyrazol-1-yl)pyrimidin-4-amine for use in the treatment of cancer
CN108348601B (zh) 与lag3结合的抗体治疗剂
JP2025060802A5 (enExample)
JP2020520665A5 (enExample)
JP2018505177A5 (enExample)
JP2019502676A5 (enExample)
JP2016507555A5 (enExample)
FI3932951T3 (fi) Menetelmiä ihosyövän hoitamiseksi antamalla PD-1-inhibiittoria
TW201023855A (en) Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
JP2009541492A5 (enExample)
JP2012501626A5 (enExample)
IL292780A (en) A new 4-1bbl trimer containing antigen-binding molecules
US20230227577A1 (en) Anti-dll3 antibodies and methods of use
JP7712925B2 (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ
US20230312738A1 (en) System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
BR112019020185A2 (pt) Métodos e composições para redução da imunogenicidade
WO2012154587A2 (en) Methods for preventing toxic drug-drug interactions in combination therapies comprising anti-erbb3 agents
JP2024054123A (ja) 癌の治療のための配合剤
TW202104263A (zh) 雙特異性CD123xCD3雙抗體在血液系統惡性腫瘤治療中的給藥方案
JP2019526244A5 (enExample)
CN119997974A (zh) 一种异源二聚体融合蛋白及其应用
TW202542198A (zh) Cd137結合分子及其用途
JP2025172885A (ja) 腫瘍治療のための二重特異性融合タンパク質